DSIP (Delta Sleep-Inducing Peptide): Neuropeptide Structure, BBB Permeability, and Research Applications

What Is DSIP?

DSIP (delta sleep-inducing peptide) is a nonapeptide first isolated in 1974 by Schoenenberger and colleagues from the cerebral venous blood of rabbits during electrophysiologically defined slow-wave sleep. Its primary sequence is: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (9 amino acids; MW ≈ 848 Da)

Despite its historical name, research since the original characterization has revealed a substantially broader neuromodulatory profile than the initial sleep-inducing characterization implies. DSIP has been examined in published research for interactions with the opioid and GABAergic systems, HPA (hypothalamic-pituitary-adrenal) axis modulation, and stress-response endpoints across multiple rodent and early human research models.

Phase 1 Peptides supplies DSIP as a research compound for laboratory use only.

Sequence and Structure

DSIP is a nine-amino-acid peptide with an unmodified N-terminus and free C-terminus. Its sequence contains:

• Tryptophan (Trp) at position 1 — an aromatic residue relevant to BBB transport mechanisms
• Glycine (Gly) at positions 3 and 4 — flexible spacers common in bioactive neuropeptides
• Aspartate (Asp) at position 5 — anionic residue
• Serine (Ser) at position 7 — hydroxyl-bearing residue, a common phosphorylation target in signaling peptides

The peptide is water-soluble and has been described as relatively stable under physiological conditions compared to other neuropeptides of similar size. Published studies report it retains bioactivity after peripheral administration in animal models — attributed in part to its documented ability to cross the blood-brain barrier.

Blood-Brain Barrier Permeability

One of DSIP's most-cited research properties is its apparent ability to cross the blood-brain barrier (BBB) intact following peripheral administration. This is pharmacologically unusual for a peptide — most peptides of 500–1000 Da are poorly penetrant across the BBB due to efflux transporters and limited transcytosis rates.

Published research has described DSIP BBB transport as involving saturable carrier-mediated mechanisms and has detected intact DSIP in brain tissue following peripheral dosing in rodent models. The mechanism of this permeability — and whether it is primarily carrier-mediated, transcytotic, or involves another route — remains an area of ongoing characterization in the published literature.

For central nervous system neuropeptide research, this BBB permeability makes DSIP a tractable tool for studying peripheral-central communication through a neuropeptide that acts centrally but can be administered peripherally in animal models.

Research Application Areas

Published research on DSIP has examined the following areas:

Sleep Architecture Models

DSIP was originally characterized in the context of slow-wave (delta-wave) sleep induction. Published animal studies have described delta-wave EEG activity changes following DSIP administration. The peptide's research role in sleep architecture is now understood as one component of a broader neuromodulatory profile rather than a simple sleep-on/sleep-off switch.

HPA Axis and Stress Response

Published studies have examined DSIP's interactions with the hypothalamic-pituitary-adrenal axis. Reported endpoints include modulation of ACTH and cortisol secretion in rodent stress models, and interactions with corticotropin-releasing hormone (CRH) pathway activity. DSIP has also been studied in published research examining its effects on glucocorticoid receptor sensitivity in stress-response experimental designs.

Opioid System and Analgesic Models

DSIP has been investigated in rodent opiate tolerance models. Published research has examined whether DSIP administration attenuates the development of tolerance to opiate analgesics, with proposed mechanisms involving GABAergic modulation and opioid receptor sensitization. This application is relevant to research examining the neuromodulatory interface between endogenous neuropeptides and the opioid receptor system.

Neuromodulatory Profile

Beyond specific receptor interactions, DSIP has been studied as a modulator of general neuronal excitability and neurotransmitter release. The peptide's broad distribution of reported effects — spanning GABAergic, opioidergic, and adrenal signaling — has made it a subject of interest in neuromodulator research rather than a narrow pharmacological tool.

Laboratory Handling Notes

DSIP is a nonapeptide supplied as a lyophilized powder. It reconstitutes readily in sterile water or bacteriostatic water. Store lyophilized at −20 °C; reconstituted solutions at 2–8 °C. Like most small neuropeptides, DSIP is sensitive to freeze-thaw cycles in reconstituted form — aliquoting before freezing is standard laboratory practice to minimize sample degradation. See the reconstitution guide for standard protocol.

Product Availability

Phase 1 Peptides stocks DSIP for laboratory research. Lot-specific third-party documentation is published where a certificate has been received; review the record for the applicable size and lot in the lab library.

Q: Why is DSIP called "delta sleep-inducing" if its research profile is broader than sleep?

DSIP was named based on its initial characterization: it was isolated from cerebral venous blood collected during delta-wave (slow-wave) sleep in rabbits, and early studies described EEG delta-wave enhancement following its administration. Subsequent research expanded its characterized effects well beyond sleep architecture to include HPA axis modulation, opioid system interactions, and stress-response endpoints. The original name has remained in the literature despite this expanded profile — a common occurrence in neuropeptide pharmacology where early characterization defines the name but not the full biological scope.

Q: How does DSIP cross the blood-brain barrier?

The mechanism of DSIP's BBB permeability is not fully resolved in the published literature. Proposed mechanisms include saturable carrier-mediated transport (possibly shared with other neuropeptides) and passive transcellular diffusion facilitated by its relatively small size. The presence of tryptophan at the N-terminus may be relevant — tryptophan interacts with large neutral amino acid (LNAA) transporters, some of which are expressed at the BBB. Most research has demonstrated BBB penetration empirically by detecting intact peptide in brain tissue following peripheral dosing.

Q: What animal models is DSIP typically studied in?

The majority of published DSIP research has used rodent models — primarily rats and mice — for both EEG sleep architecture studies and HPA axis endpoints. Some early clinical research (primarily from European institutions in the 1970s–1990s) examined DSIP administration in human subjects for sleep-related endpoints, though this research is methodologically dated by current standards. Modern research primarily uses rodent in vivo models and ex vivo brain tissue preparations.

For a three-way comparison of Semax, Selank, and DSIP as neuropeptide research tools, see the Neuropeptide Research overview.

See Also

• Semax Research Primer — ACTH-derived neuropeptide studied for cognitive and neuroprotective applications
• Selank Research Primer — anxiolytic neuropeptide with immunomodulatory activity
• Peptide Half-Life Reference — pharmacokinetic data including DSIP's rapid clearance profile
• Lab Testing & Verified Purity — how HPLC and mass spectrometry verify research peptide quality
• How to Reconstitute Research Peptides — standard laboratory reconstitution workflow for neuropeptide research

All Phase 1 Peptides products are supplied exclusively for laboratory research and in vitro studies. They are not intended for human or animal consumption, clinical use, or therapeutic application.